Evidence map›Paper›PMID 41845035›Full record

ArticleThe Journal of antibiotics2026

A non-antibiotic genetic selection system enables near-infrared in vivo imaging and evaluation of antibiotic efficacy for multidrug-resistant Acinetobacter baumannii.

Daiki Yamaguchi, Go Kamoshida, Takato Asami, Maki Kabumoto, Mami Kobayashi, Yuna Oshima, Hikaru Kitamura, Tsubasa Otsuka, Nobuo Kitada, Ryohei Saito-Moriya and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Daiki YamaguchiDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan.ORCID http://orcid.org/0009-0009-5581-7089
Go KamoshidaDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan. kamoshida@my-pharm.ac.jp.
Takato AsamiDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan.
Maki KabumotoLaboratory of Microbiology and Infection Control, Kyoto Pharmaceutical University, Kyoto, Japan.
Mami KobayashiLaboratory of Microbiology and Infection Control, Kyoto Pharmaceutical University, Kyoto, Japan.
Yuna OshimaLaboratory of Microbiology and Infection Control, Kyoto Pharmaceutical University, Kyoto, Japan.
Hikaru KitamuraDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan.
Tsubasa OtsukaDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan.
Nobuo KitadaGraduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Ryohei Saito-MoriyaDepartment of Chemistry, School of Science, Kitasato University, Minato City, Japan.
Yuki KayaDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan.
Noriteru YamadaLaboratory of Microbiology and Infection Control, Kyoto Pharmaceutical University, Kyoto, Japan.
Ryuichi NakanoDepartment of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan.ORCID http://orcid.org/0000-0003-2086-2591
Hisakazu YanoDepartment of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan.
Kinnosuke YahiroLaboratory of Microbiology and Infection Control, Kyoto Pharmaceutical University, Kyoto, Japan.
Shojiro A MakiGraduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Yuji MoritaDepartment of Infection Control Science, Meiji Pharmaceutical University, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development (AMED) 23fk0108611h0903MEXT | Japan Society for the Promotion of Science (JSPS) 20K17475, 24K10208
6 · The paper itself

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAb) is designated by the World Health Organization as a critical priority pathogen, and most clinical CRAb isolates are multidrug-resistant (MDRA). However, an in vivo mouse imaging model of infection using clinical MDRA isolates has not been curated. Using antibiotic resistance genes as plasmid selection markers is incompatible with antimicrobial drug evaluation and prevents their application to MDRA isolates. To overcome this limitation, we constructed a firefly luciferase plasmid using tellurite resistance genes as non-antibiotic selection markers, enabling luminescence in multiple clinical MDRA isolates without altering susceptibility. Using a mouse pneumonia model and near-infrared luciferin derivative (TokeOni), we achieved noninvasive visualization of lung colonization by clinical MDRA isolates. Luminescence dynamics during treatment mirrored the in vitro minimum inhibitory concentration and survival outcomes, providing a therapeutic response readout. This platform overcomes a major bottleneck in MDR pathogen imaging and supports the evaluation of infection dynamics and drug efficacy.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialAnimalsDisease Models, AnimalFemaleHumansMiceMicrobial Sensitivity TestsPlasmidsAnti-Bacterial Agents

Identifiers

PMID41845035

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.